Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.

Authors

Lorea Iturri, Sarah Potiron, Liangchao Sun, Marjorie Juchaux, Cristèle Gilbert, Julie Espenon, Ignacio Anegon, Severine Ménoret, Carole Soussain, Sebastián Amigorena, Marion Alcantara, Yolanda Prezado

Published in

iScience. Volume 29. Issue 11. Pages 117827. Nov 20, 2026. Epub Oct 08, 2026.

Abstract

Radiotherapy is increasingly combined with CAR T cell therapy in B cell lymphomas, but treatment outcome may depend on the irradiation modality. We evaluated minibeam radiation therapy (MBRT) as a partner for CD19 CAR T cells in an orthotopic primary central nervous system (CNS) lymphoma model in immunodeficient rats. CAR T therapy prolonged survival compared with untreated controls. MBRT at 30 Gy followed by CAR T cells five days later produced the longest median survival among radiotherapy-containing regimens and improved outcome compared with conventional radiotherapy (CRT) based combinations. Histopathological findings were consistent with these survival differences. However, MBRT plus CAR T therapy did not significantly outperform CAR T monotherapy. These results indicate that MBRT provides a favorable, non-antagonistic radiotherapy context for CAR T therapy and suggest that radiation modality should be considered when designing combinations of radiotherapy with adoptive cellular therapies.

PMID:
42898331
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.